🇺🇸 fenoterol/ipratropium bromide in United States

99 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 12 reports (12.12%)
  2. General Physical Health Deterioration — 12 reports (12.12%)
  3. Off Label Use — 12 reports (12.12%)
  4. Asthma — 10 reports (10.1%)
  5. Chronic Obstructive Pulmonary Disease — 10 reports (10.1%)
  6. Dyspnoea — 10 reports (10.1%)
  7. Dizziness — 9 reports (9.09%)
  8. Anaemia — 8 reports (8.08%)
  9. Condition Aggravated — 8 reports (8.08%)
  10. Hypotension — 8 reports (8.08%)

Source database →

Other Respiratory / Pulmonology approved in United States

Frequently asked questions

Is fenoterol/ipratropium bromide approved in United States?

fenoterol/ipratropium bromide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for fenoterol/ipratropium bromide in United States?

Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.